A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

Summary

The purpose of this study is to determine the efficacy of tirzepatide in participants with type 2 diabetes.

Timeline

Start

2017-10-19

Primary completion

2018-04-24

Completion

2018-04-24

Outcome

Met primary endpoint

registry analysis (superiority test); Placebo vs 4, 8 and 12mg Tirzepatide; p <0.001; Mean Difference (Final Values) -1.9 (95% CI -2.5 to -1.4); Mixed Models Analysis NCT03311724 ↗

Drugs

Indications